CTC and Tumor Related Rare Cell Clinical Trial
Official title:
Identification and Evaluation of the Potential Biomarkers on Circulating Tumor Cells and Tumor Related Rare Cells in Cancer Patients Undergoing Immunotherapy
The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome. The secondary objective is to explore whether the changes of tumor related rare cells associates clinical outcome.
| Status | Recruiting |
| Enrollment | 80 |
| Est. completion date | April 30, 2020 |
| Est. primary completion date | December 30, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 20 Years and older |
| Eligibility |
Inclusion Criteria: 1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study. 2. Over 20 years of age. 3. Cancer patients on immune checkpoint inhibitors. Exclusion Criteria: 1. Subjects who have other cancer history 2. Pregnant females 3. Subjects with active, known or suspected autoimmune disease. 4. Known history of human immunodeficiency virus (HIV) |
| Country | Name | City | State |
|---|---|---|---|
| Taiwan | Taipei Veterans General Hospital | Taipei |
| Lead Sponsor | Collaborator |
|---|---|
| MiCareo Taiwan Co., Ltd. | Taipei Veterans General Hospital, Taiwan |
Taiwan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Circulating tumor cell | Isolation and analysis of circulating tumor cells before and after immunotherapy | 1 years | |
| Secondary | tumor related rare cell | Isolation and analysis of tumor related rare cells before and after immunotherapy | 1 years |